Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 10/2018

01-10-2018 | Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options

Authors: Nikolaos Vassos, MD, Pompiliu Piso, MD

Published in: Current Treatment Options in Oncology | Issue 10/2018

Login to get access

Opinion statement

Peritoneal metastases (PM) are common in advanced-stage colorectal cancer (CRC) patients representing the second most common metastatic site of CRC. In the past, this clinical situation was treated with palliative intent. The introduction of new chemotherapeutic and targeted biologic agents has improved the prognosis of patients with metastatic colorectal cancer. However, the inclusion of treatment options such as cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as inherent components of a multidisciplinary treatment was evolving for the management of these patients. Notably, the surgical approach of CRS/HIPEC has been effective offering a prolonged survival with curative intent in patients with colorectal PM. This article reviews and highlights the recent evidence of CRS and HIPEC as well as current research going on in this form of locoregional treatment in the setting of peritoneal metastases of colorectal cancer.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef
2.
van Gestel YRBM, de Hingh IHJT, van Herk-Sukel MPP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38:448–54.PubMedCrossRef
3.
Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717–25.PubMedCrossRef
4.
Segelman J, Granath F, Holm T, et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99:699–705.PubMedCrossRef
5.
UICC. TNM classification of malignant tumors. 8th ed. New York: Wiley; 2017.
6.
Sobin LH, Gospondarowicz MK, Wittekind C. TNM classification of malignant tumors. UICC International Union against Cancer. ed. 7 ed. New York: Wiley; 2009. p. 100–5.
7.
Brooks GA, Abrams TA, Meyerhardt JA, et al. Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol. 2014;32:296–303.CrossRef
8.
Van Gestel YR, Thomassen I, Lemmens VE, et al. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol. 2014;40:963–9.PubMedCrossRef
9.
Sugarbaker P. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker P, editor. Peritoneal carcinomatosis: principles of management, vol. 1996. Boston: Kluwer Academic Publishers; 1996. p. 79–100.CrossRef
10.
Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynelogic malignancies. Surg Oncol Clin N Am. 2003;12:729–39.PubMedCrossRef
11.
Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108:1432–9.PubMedPubMedCentralCrossRef
12.
Segelman J, Akre O, Gustafsson UO, et al. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Color Dis. 2014;16:359–67.CrossRef
13.
Ozawa H, Kotake K, Kobayashi H, et al. Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today. 2014;44:1643–50.PubMedCrossRef
14.
Sato H, Kotake K, Sugihara K, Takahashi H, et al. Clinicopathological factors associated with recurrence and prognosis after R0-resection for stage IV colorectal cancer with peritoneal metastasis. Dig Surg. 2016;33:382–91.PubMedCrossRef
15.
Kaneko M, Ishihara S, Murono K, et al. Carbohydrate antigen 19-9 predicts synchronous peritoneal carcinomatosis in patients with colorectal cancer. Anticancer Res. 2017;37:865–70.PubMedCrossRef
16.
Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1–10.PubMedCrossRef
17.
18.
Esquivel J, Elias D, Barrati D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98:263–7.PubMedCrossRef
19.
Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.PubMed
20.
Sugarbaker PH, Ronnet BM, Archer A, et al. Management of pseudomyxoma peritonei of appendiceal origin. Adv Surg. 1997;30:233–80.
21.
22.
Mirnezami R, Moran BJ, Harvey K, et al. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol. 2014;20:14018–32.PubMedPubMedCentralCrossRef
23.
Goéré D, Gras-Chaput N, Aupérin A, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14:148.PubMedPubMedCentralCrossRef
24.
Verhulst J. Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Hyperth. 2013;29:62–70.CrossRef
25.
Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501–5.PubMedCrossRef
26.
Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Surg Oncol. 2002;13:267–72.CrossRef
27.
Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818–24.PubMedCrossRef
28.
Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111:1500–8.PubMedPubMedCentralCrossRef
29.
Verwaal VC, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis from colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRef
30.
Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518–21.PubMedCrossRef
31.
Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403–7.PubMedPubMedCentralCrossRef
32.
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRef
33.
Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.PubMedCrossRef
34.
Mulsow J, Merkel S, Agaimy A, Hohenberger W. Outcomes following surgery for colorectal cancer with synchronous peritoneal metastases. Br J Surg. 2011;98:1785–91.PubMedCrossRef
35.
Matsuda K, Hotta T, Takifuji K, Yamamoto M, Nasu T, Togo N, et al. Clinical impact of a macroscopically complete resection of colorectal cancer with peritoneal carcinomatosis. Surgery. 2012;151:238–44.PubMedCrossRef
36.
Désolneux G, Mazière C, Vara J, et al. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One. 2015;10(3):e0122816.PubMedPubMedCentralCrossRef
37.
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRef
38.
Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65–71.PubMedCrossRef
39.
Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin. Long term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol. 2006;30:12004.
40.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
41.
Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224–30.PubMedPubMedCentralCrossRef
42.
Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.PubMedCrossRef
43.
Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomized trial. Eur J Cancer. 2016;53:155–62.PubMedCrossRef
44.
Losa F, Barrios P, Salazar R, et al. Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol. 2014;16:128–40.PubMedCrossRef
45.
•• Quenet J, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 36, 2018 (suppl; abstr LBA3503). This trial evaluates the specifics role of HIPEC, after CRS, for the treatment of PM of colorectal origin. The therapeutic curative management of PC from CRC by CRS shows satisfactory survival results. First results show that the addition of HIPEC with oxaliplatin does not influence the OS.
46.
Esquivel J, Piso P, Verwaal V, et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110:777–8.PubMedCrossRef
47.
O'Dwyer S, Verwaal VJ, Sugarbaker PH. Evolution of treatments for peritoneal metastases from colorectal cancer. J Clin Oncol. 2015;33:2122–3.PubMedCrossRef
48.
•• Benson AB 3rd, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netq. 2018;16:359–69. These newest NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship and are published in April, 2018.CrossRef
49.
Saxena A, Yan TD, Morris DL. A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. World J Surg. 2010;34:70–8.PubMedCrossRef
50.
Ihemelandu CU, McQuellon R, Shen R, et al. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS + HIPEC) with preoperative FACT-C (functional assessment of cancer therapy) and patient-rated performance status. Ann Surg Oncol. 2013;20:3519–26.PubMedCrossRef
51.
Kusamura S, Younaan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRef
52.
Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMedCrossRef
53.
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRef
54.
Levine SJH, Russell GB, Geisinger KR, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204:943–53.PubMedCrossRef
55.
Kzu M, Koksoy C, Kale T, et al. Experimental study of the effect of preoperative 5-fluorouracil on integrity of colon anastomoses. Br J Surg. 1998;85:236–9.CrossRef
56.
Shimizu T, Maeta K, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg. 1991;78:55–9.CrossRef
57.
El-Nakeep S, Rashad N, Oweira H, et al. Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. Expert Rev Gastroenterol Hepatol. 2017;11:249–58.PubMed
58.
Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases - a metaanalysis. Ann Surg. 2016;263:1102–11.PubMedCrossRef
59.
Elias D, Benizri E, Pocard M, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol. 2006;32:632–6.PubMedCrossRef
60.
März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf). 2015;3:298–302.
61.
62.
•• Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102–11. The most recent meta-analysis evaluating clinicopathological parameters for patient selection for CRC and HIPEC for CRC metastases.PubMedCrossRef
63.
Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21:2608–14.PubMedCrossRef
64.
Cavaliere F, De Simone M, Virz S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37:148–54.PubMedCrossRef
65.
Yonemura Y, Canbay E, Ishibashi H. Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J. 2013;2013
66.
Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.PubMedCrossRef
67.
Goéré D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.
68.
Quenet F, Goéré D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg.
69.
Simkens GA, Razenberg LG, Lemmens VE, et al. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol. 2016;42:794–800.PubMedCrossRef
70.
van Oudheusden T, Braam H, Nienhuijs S, et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111:237.PubMedCrossRef
71.
Baumgartner JM, Tobin L, Heavey SF, et al. Predictors of progression in highgrade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22:1716–21.PubMedCrossRef
72.
Matsuda K, Hotta T, Takifuji K, et al. Lymph nodes ratio is associated with the survival of colorectal cancer patients with peritoneal carcinomatosis. Am Surg. 2011;77:602–67.PubMed
73.
Randle RW, Doud AN, Levine EA, et al. Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015;22:1634–8.PubMedCrossRef
74.
Maggiori L, Goéré D, Viana B, et al. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg. 2013;258:116–21.PubMedCrossRef
75.
Delhorme JB, Dupont-Kazma L, Addeo P, et al. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: who will benefit from complete cytoreductive surgery? Int J Surg. 2016;25:98–105.PubMedCrossRef
76.
Nishikawa T, Sunami E, Tanaka T, et al. Incidence and prognostic significance of positive peritoneal lavage in colorectal cancer. Surg Today. 2015;45:1073–81.PubMedCrossRef
77.
Homma Y, Hamano T, Akazawa Y, et al. Positive peritoneal washing cytology is a potential risk factor for the recurrence of curatively resected colorectal cancer. Surg Today. 2014;44:1084–9.PubMedCrossRef
78.
Pelz JOW, Stojadinovic A, Nissan A, et al. Evaluation of a Peritoneal Surface Disease Severity Score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15.PubMedCrossRef
79.
Pelz JO, Chua TC, Esquivel J, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689.PubMedPubMedCentralCrossRef
80.
Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:4195–01.PubMedCrossRef
81.
Ng JL, Ong WS, Chia CS, et al. Prognostic relevance of the Peritoneal Surface Disease Severity Score compared to the peritoneal cancer index for colorectal peritoneal carcinomatosis. Int J Surg Oncol. 2016;2016:2495131.PubMedPubMedCentral
82.
Chua TC, Morris DL, Esquivel J. Impact of the Peritoneal Surface Disease Severity Score on survival in patients with colorectal cancer undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.PubMedCrossRef
83.
• Simkens GA, van Oudheusden TR, Nieboer D, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol. 2016;23:4214–21. This study externally validates the Peritoneal Surface Disease Severity Score (PSDSS) in patients with colorectal PM treated with CRS and HIPEC and develops a new prognostic model, the COMPASS.PubMedCrossRef
84.
Cashin PH, Graf W, Nygren P, Mahteme H. Comparison of prognostic scores for patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:4183–9.PubMedCrossRef
85.
Verwaal VJ, Boot H, Aleman BM, et al. Recurrences after peritoneal ca5rcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.PubMedCrossRef
86.
van Oudheusden TR, Nienhuijs SW, Luyer MD, Nieuwenhuijzen GA, Lemmens VE, Rutten HJ, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41:1269–77.PubMedCrossRef
87.
Bijelic L, Yan D, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2007;14:2281–8.PubMedCrossRef
88.
Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol. 2012;106:197–203.PubMedCrossRef
89.
Elias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011;254:289–93.PubMedCrossRef
90.
Votanopoulos KI, Ihemelandu C, Shen P, et al. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215:412–7.PubMedPubMedCentralCrossRef
91.
Williams BH, Alzahrani NA, Chan DL, et al. Repeat cytoreductive surgery (CRS) for recurrent colorectal peritoneal metastases: yes or no? Eur J Surg Oncol. 2013;40:943–9.PubMedCrossRef
92.
Vassos N, Förtsch T, Aladashvili A, et al. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. World J Surg Oncol. 2016;14:42.PubMedPubMedCentralCrossRef
93.
Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19:1416–24.PubMedCrossRef
94.
Law WL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol. 2007;14:2559–66.PubMedCrossRef
95.
Kondo Y, Murayama Y, Konishi H, et al. Fluorescent detection of peritoneal metastasis in human colorectal cancer using 5-aminolevulinic acid. Int J Oncol. 2014;45:41–6.PubMedPubMedCentralCrossRef
96.
Klumpp B, Schwenzer NF, Gatidis S, et al. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT. RoFo. 2014;186:359–66.PubMedCrossRef
97.
Wangensteen OH. Cancer of the colon and rectum; with special reference to earlier recognition of alimentary tract malignancy; secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement; subtotal primary excision of the colon; operation in obstruction. Wis Med J. 1949;48:591–7.PubMed
98.
Gilbersten VA, Wangensteen OH. A summary of thirteen years’ experience with the second look program. Surg Gynecol Obstet. 1962;114:438–42.
99.
Elias D, Goere D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445–50.PubMedCrossRef
100.
Honoré C, Goéré D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013;20:183–92.PubMedCrossRef
101.
• Pinto A, Eveno C, Pocard M. Update on clinical trials in colorectal cancer peritoneal metastasis. Int J Hyperth. 2017;33:543–7. This review provides a update on recruiting clinical trials evaluating CRS and HIPEC in the prevention or therapy of colorectal PM.CrossRef
102.
Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol. 2016;7:72–8.PubMedPubMedCentralCrossRef
103.
Sammartino P, Sibio S, Biacchi D, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585.PubMedPubMedCentralCrossRef
104.
Klaver CEL, Stam R, Sloothaak DAM, et al. Colorectal cancer at high risk of peritoneal metastases: long term outcomes of a pilot study on adjuvant laparoscopic HIPEC and future perspectives. Oncotarget. 2017;8:51200–9.PubMedPubMedCentralCrossRef
105.
Sugarbaker PH, Gianola FJ, Speyer JL, et al. Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol. 1985;12:101–11.PubMed
106.
Graf W, Westlin JE, Pahlman L, Glimelius B. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study. Int J Color Dis. 1994;9:35–9.CrossRef
107.
• Klaver CE, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428. The outcomes of the COLOPEC randomized multicentre trial should be awaited for definitive conclusions on the effectiveness of adjuvant HIPEC.PubMedPubMedCentralCrossRef
108.
• Ariona-Sanchez A, Bariios P, Boldo-Roda E, et al. HIPECT4: mutlicentre, randomized clinical trial to evaluate safety and efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer. 2018;18:183. The HIPECT4 randomized controlled trial will determine the effectiveness and safety of adjuvant HIPEC vs. standard treatment in patients with colon cancer at high risk of peritoneal recurrence (pT4).CrossRef
109.
Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682–5.PubMedCrossRef
110.
Valle SJ, Alzahrani NA, Alzahrani SE, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg. 2015;23:176–80.PubMedCrossRef
111.
Glockzin G, Schlitt HJ, Piso P. Therapeutic options for peritoneal metastasis arising from colorectal cancer. World J Gastrointest Pharmacol Ther. 2016;7:343–52.PubMedPubMedCentralCrossRef
112.
Sloothaak DA, Gardenbroek TJ, Crezee J, et al. Feasibility of adjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in a short stay setting in patients with colorectal cancer at high risk of peritoneal carcinomatosis. Eur J Surg Oncol. 2014;40:1453–8.PubMedCrossRef
113.
Baratti D, Kusamura S, Deraco M. Prevention and early treatment of peritoneal metastases from colorectal cancer: second-Look laparotomy or prophylactic HIPEC? J Surg Oncol. 2014;109:225–6.PubMedCrossRef
114.
Kok NF, de Hingh IH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Br J Surg. 2017;104:313–5.PubMedCrossRef
115.
Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20:3504–11.PubMedPubMedCentralCrossRef
116.
Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.PubMedPubMedCentralCrossRef
117.
Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41:1379–85.PubMedCrossRef
118.
Tempfer CB, Rezniczek GA, Ende P, et al. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. Anticancer Res. 2015;35:6723–9.PubMed
119.
Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016;18:364–71.CrossRef
120.
• Grass F, Vuagniaux A, Teixeira-Farihna H, et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017;104:669–78. This is the first systematic review of the literature on pressurized intraperitoneal chemotherapy (PIPAC) and of the available evidence on mechanisms, clinical effects and risks.PubMedCrossRef
Metadata
Title
Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options
Authors
Nikolaos Vassos, MD
Pompiliu Piso, MD
Publication date
01-10-2018
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 10/2018
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-018-0563-8

Other articles of this Issue 10/2018

Current Treatment Options in Oncology 10/2018 Go to the issue

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Harnessing the Immune System in Pancreatic Cancer

Skin Cancer (T Ito, Section Editor)

Prognostic Factors of Extramammary Paget’s Disease

Lymphoma (DO Persky, Section Editor)

Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Quality Control of Radiation Delivery for Lower Gastrointestinal Cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits